Showing metabocard for CL(i-16:0/a-17:0/a-21:0/23:0) (HMDB0240149)
| Record Information | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Version | 5.0 | |||||||||||||||
| Status | Predicted | |||||||||||||||
| Creation Date | 2017-10-17 16:56:17 UTC | |||||||||||||||
| Update Date | 2022-11-30 19:53:40 UTC | |||||||||||||||
| HMDB ID | HMDB0240149 | |||||||||||||||
| Secondary Accession Numbers | None | |||||||||||||||
| Metabolite Identification | ||||||||||||||||
| Common Name | CL(i-16:0/a-17:0/a-21:0/23:0) | |||||||||||||||
| Description | CL(i-16:0/a-17:0/a-21:0/23:0) is a cardiolipin (CL). Cardiolipins are sometimes called a 'double' phospholipid because they have four fatty acid tails, instead of the usual two. CL(i-16:0/a-17:0/a-21:0/23:0) contains one chain of 14-methylpentadecanoic acid at the C1 position, one chain of 14-methylhexadecanoic acid at the C2 position, one chain of 18-methyleicosanoic acid at the C3 position, one chain of tricosanoic acid at the C4 position. Cardiolipins are known to be present in all mammalian cells especially cells with a high number of mitochondria. De novo synthesis of Cardiolipins begins with condensing phosphatidic acid (PA) with cytidine-5’-triphosphate (CTP) to form cytidine-diphosphate-1,2-diacyl-sn-glycerol (CDP- DG). Glycerol-3-phosphate is subsequently added to this newly formed CDP-DG molecule to form phosphatidylglycerol phosphate (PGP), which is immediately dephosphorylated to form PG. The final step is the process of condensing the PG molecule with another CDP-DG molecule to form a new cardiolipin, which is catalyzed by cardiolipin synthase. All new cardiolipins will immediately undergo a series remodeling resulting in the common cardiolipin compositions. (PMID:16442164 ). Cardiolipin synthase shows no selectivity for fatty acyl chains used in the de novo synthesis of cardiolipin (PMID:16442164 ). Tafazzin is an important enzyme in the remodeling of cardiolipins, and opposite to cardiolipin synthase, it shows strong acyl specificity. This suggest that the specificity in cardiolipin composition is achieved through the remodeling steps. Mutation in the tafazzin gene disrupts the remodeling of cardiolipin and is the cause of Barth syndrome (BTHS), a X-linked human disease (PMID: 16973164 ). BTHS patients seems to lack acyl specificity and as a result, there are many potential cardiolipin species that can exists (PMID: 16226238 ). Common fatty acyl chains determined through methods such as gas chromatography and high-performance liquid chromatography are used to generate various cardiolipins and a representative molecule is chosen from each variation. | |||||||||||||||
| Structure | Structure for HMDB0240149 (CL(i-16:0/a-17:0/a-21:0/23:0))
| |||||||||||||||
| Synonyms | Not Available | |||||||||||||||
| Chemical Formula | Not Available | |||||||||||||||
| Average Molecular Weight | Not Available | |||||||||||||||
| Monoisotopic Molecular Weight | Not Available | |||||||||||||||
| IUPAC Name | Not Available | |||||||||||||||
| Traditional Name | Not Available | |||||||||||||||
| CAS Registry Number | Not Available | |||||||||||||||
| SMILES | Not Available | |||||||||||||||
| InChI Identifier | Not Available | |||||||||||||||
| InChI Key | Not Available | |||||||||||||||
| Chemical Taxonomy | ||||||||||||||||
| Classification | Not classified | |||||||||||||||
| Ontology | ||||||||||||||||
| Not Available | Not Available | |||||||||||||||
| Physical Properties | ||||||||||||||||
| State | Not Available | |||||||||||||||
| Experimental Molecular Properties |
| |||||||||||||||
| Experimental Chromatographic Properties | ||||||||||||||||
| Predicted Molecular Properties | Not Available | |||||||||||||||
| Predicted Chromatographic Properties | Predicted Kovats Retention IndicesNot Available | |||||||||||||||
| Spectra | ||||||||||||||||
| Biological Properties | ||||||||||||||||
| Cellular Locations | Not Available | |||||||||||||||
| Biospecimen Locations | Not Available | |||||||||||||||
| Tissue Locations | Not Available | |||||||||||||||
| Pathways |
| |||||||||||||||
| Normal Concentrations | ||||||||||||||||
| Not Available | ||||||||||||||||
| Abnormal Concentrations | ||||||||||||||||
| Not Available | ||||||||||||||||
| Associated Disorders and Diseases | ||||||||||||||||
| Disease References | None | |||||||||||||||
| Associated OMIM IDs | None | |||||||||||||||
| External Links | ||||||||||||||||
| External Links | Not Available | |||||||||||||||
| References | ||||||||||||||||
| Synthesis Reference | Not Available | |||||||||||||||
| Material Safety Data Sheet (MSDS) | Not Available | |||||||||||||||
| General References |
| |||||||||||||||
